• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Alzheimer’s disease

Articles Tagged with ''Alzheimer’s disease''

Axsome strengthens with more positive Alzheimer's data

Nov. 28, 2022
By Lee Landenberger
Axsome Therapeutics Inc.’s AXS-05 (dextromethorphan + bupropion) has notched another success by hitting its phase III primary endpoint in treating a notoriously difficult Alzheimer’s disease (AD) indication when compared to placebo. Newly released data from the Accord study showed AXS-05, an oral, NMDA receptor antagonist with multimodal activity, statistically significantly delayed time to relapse of AD agitation vs. placebo (p=0.014), which was the primary endpoint.
Read More
Neurology/Psychiatric

Insulin signaling in brain cells tied to Alzheimer's disease pathology

Nov. 28, 2022
Brain insulin signaling is known to control peripheral energy metabolism and regulation of mood and cognition. Dysregulation in this signaling has been tied to brain pathological disorders such as Alzheimer’s disease (AD). Previous findings have reported a strong connection between type 2 diabetes (T2D) and AD, suggesting insulin resistance as a potential risk factor for AD pathology and other forms of dementia.
Read More
Wearable ANI Guardian device on forearm

Mdoloris and Pprs launch non-invasive pain monitor for non-communicative patients

Nov. 22, 2022
By Bernard Banga
Mdoloris Medical Systems SAS and Pprs SAS reported a joint venture to launch ANI Guardian, a connected medical device that continuously and non-invasively tracks pain levels and well-being in a range of non-verbal or cognitively impaired people.
Read More
Brain with handshake and cityscape
Neurology/Psychiatric

Attralus and Ossianix agree to use TXP1 brain shuttle to deliver AT-04 for neurodegenerative diseases

Nov. 18, 2022
Attralus Inc. and Ossianix Inc. have entered into...
Read More
Brain samples of people with APOE3/4 vs. APOE3/3
Neurology/Psychiatric

APOE4 allele reduces myelination in Alzheimer’s disease

Nov. 16, 2022
By Mar de Miguel
Carrying the apolipoprotein E4 allele (APOE4), and not the APOE3 variant, is the strongest risk factor for developing Alzheimer’s disease (AD). But the underlying mechanism has remained elusive. Now, researchers at MIT and Mount Sinai have found that in brains carrying the APOE4 allele, lipid and cholesterol processes were dysregulated in oligodendrocytes and that this effect reduced myelination.
Read More
Amyloid plaques forming between neurons

Genentech data reveal ongoing challenge of targeting amyloid beta

Nov. 14, 2022
By Lee Landenberger
Two phase III failures with Roche Holding AG subsidiary Genentech Inc.’s gantenerumab in staving off mild cognitive impairment tied to Alzheimer’s disease (AD) revealed the level of amyloid-beta removal was lower than the company expected. The protein amyloid beta accumulates in the brains of AD patients and its removal is suspected to be an eventual boon to AD patients. But there are still plenty of doubts. Top-line results from Genentech’s phase III Graduate I and II studies show gantenerumab, a fully human monoclonal IgG1 antibody, missed the primary endpoints of slowing clinical decline in those with mild cognitive impairment due to AD and mild AD dementia.
Read More
Neurology/Psychiatric

University of Texas System and MIT researchers divulge PU.1 inhibitors for Alzheimer's disease

Nov. 8, 2022
The University of Texas System and Massachusetts Institute of Technology (MIT) have synthesized transcription factor PU.1 inhibitors reported to be useful for the treatment of Alzheimer's disease.
Read More
Healthy brain and brain with severe Alzheimer's disease
Neurology/Psychiatric

BACH1 blockade attenuates AD progression in mice

Oct. 25, 2022
Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach.
Read More
Neurology/Psychiatric

Peptide aptamer 8 improves memory in Alzheimer’s disease model

Oct. 21, 2022
University of Calgary scientists described their work on a small peptide aptamer 8 to bind cellular prion protein and prevent its binding with β-amyloid oligomers, an interaction that activates tyrosine-protein kinase Fyn and neuroinflammation.
Read More
Toy bulldozer moving FDA letter blocks

FDA breakthrough device designation stimulates increased interest in Sinaptica

Oct. 19, 2022
By Annette Boyle
Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough device designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, brain wave monitoring and artificial intelligence (AI) to address the cognitive and functional decline in patients with the neurological disorder.
Read More
Previous 1 2 … 42 43 44 45 46 47 48 49 50 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 21, 2025.
  • Elderly woman holding illustration of brain with missing puzzle piece

    Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease

    BioWorld Science
    Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...
  • Wooden blocks spelling TARIFFS with a U.S. flag on top, placed on a map of Europe

    EU, US lock in 15% max Rx tariff, no relief for medtech

    BioWorld
    No matter what level of tariff the Trump administration ends up imposing on biopharmaceuticals across the world, drugs and their precursors originating in the EU...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for August 19, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe